JP2021525530A5 - - Google Patents
Info
- Publication number
- JP2021525530A5 JP2021525530A5 JP2020567078A JP2020567078A JP2021525530A5 JP 2021525530 A5 JP2021525530 A5 JP 2021525530A5 JP 2020567078 A JP2020567078 A JP 2020567078A JP 2020567078 A JP2020567078 A JP 2020567078A JP 2021525530 A5 JP2021525530 A5 JP 2021525530A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- ggggs
- antigen
- recognition domain
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679597P | 2018-06-01 | 2018-06-01 | |
| US62/679,597 | 2018-06-01 | ||
| PCT/US2019/034981 WO2019232425A1 (en) | 2018-06-01 | 2019-05-31 | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021525530A JP2021525530A (ja) | 2021-09-27 |
| JP2021525530A5 true JP2021525530A5 (enExample) | 2022-06-30 |
Family
ID=68696762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567078A Pending JP2021525530A (ja) | 2018-06-01 | 2019-05-31 | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20200054675A1 (enExample) |
| EP (1) | EP3802578A4 (enExample) |
| JP (1) | JP2021525530A (enExample) |
| CN (1) | CN112533942A (enExample) |
| WO (1) | WO2019232425A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102546839B1 (ko) | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| EP3802798A4 (en) * | 2018-05-31 | 2022-05-11 | Washington University | CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR TREATMENT OF CANCER |
| EP3801568A4 (en) * | 2018-05-31 | 2022-03-16 | Washington University | GENOMIC-EDITED INVARIANT NATURAL KILLER T CELLS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES |
| EP3802578A4 (en) | 2018-06-01 | 2022-03-23 | Washington University | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| AU2020232216B2 (en) | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| US12528856B2 (en) | 2019-08-30 | 2026-01-20 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising TGF β binding domains |
| EP4076476A4 (en) * | 2019-12-17 | 2023-11-22 | The General Hospital Corporation | MODIFIED IMMUNE CELLS WITH REDUCED TOXICITY AND THEIR USES |
| EP3845646A1 (en) * | 2019-12-30 | 2021-07-07 | Secarna Pharmaceuticals GmbH & Co. KG | Modified antisense oligonucleotide for inhibition of foxp3 expression |
| MX2022010340A (es) * | 2020-02-24 | 2022-09-19 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas. |
| WO2021207150A1 (en) * | 2020-04-06 | 2021-10-14 | Celledit Llc | Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling |
| CN111548420B (zh) * | 2020-05-14 | 2021-10-15 | 深圳普瑞金生物药业有限公司 | 一种抗间皮素嵌合抗原受体、表达基因、表达载体、t细胞及其用途 |
| WO2022098756A1 (en) * | 2020-11-03 | 2022-05-12 | WUGEN, Inc. | Chimeric antigen receptor cell therapy |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022161502A1 (zh) * | 2021-02-01 | 2022-08-04 | 羿尊生物医药（浙江）有限公司 | 一种靶向蛋白降解系统及其应用 |
| CN112876535B (zh) * | 2021-02-08 | 2023-06-30 | 浙江华缔药业集团医药开发有限公司 | 生物活性多肽及其应用 |
| KR20240095529A (ko) * | 2021-07-16 | 2024-06-25 | 오르토바이오 테라퓨틱스, 인크. | 관절 기능 개선을 위한 유전자 편집 |
| CN118056012B (zh) * | 2021-08-24 | 2025-05-30 | 赛斯尔擎生物技术（上海）有限公司 | 一种修饰细胞的方法 |
| CN114410686B (zh) * | 2021-12-24 | 2023-10-03 | 武汉大学 | 一种工程化外泌体原位纳米疫苗及其制备方法和应用 |
| US20250197811A1 (en) * | 2022-03-22 | 2025-06-19 | Celyntra Therapeutics Sa | Compositions and methods for generating cells with reduced immunogenicity |
| US20250302918A1 (en) * | 2022-05-20 | 2025-10-02 | President And Fellows Of Harvard College | Methods and compositions relating to treatment of cns diseases |
| CN116102662A (zh) * | 2022-10-10 | 2023-05-12 | 武汉波睿达生物科技有限公司 | 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用 |
| EP4604966A1 (en) * | 2022-10-20 | 2025-08-27 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| CN120712097A (zh) * | 2022-10-20 | 2025-09-26 | 微克立思尔私人有限公司 | 免疫疗法中细胞因子释放综合征的减轻 |
| JP2025535441A (ja) * | 2022-10-20 | 2025-10-24 | マイクロ クリスパー プライベート リミテッド | 免疫療法におけるサイトカイン放出症候群の軽減 |
| CN116240173B (zh) * | 2023-02-02 | 2024-09-27 | 西安电子科技大学 | 一种冷热肿瘤调控型car-单核/巨噬细胞及其制备方法和应用 |
| CN120098126A (zh) * | 2023-02-22 | 2025-06-06 | 成都优赛诺生物科技有限公司 | 一种靶向cd22的单域抗体、嵌合抗原受体及其应用 |
| CN116754774B (zh) * | 2023-05-12 | 2026-03-06 | 浙江大学医学院附属第一医院 | 一种细胞因子组合物及应用 |
| WO2025077790A1 (en) * | 2023-10-11 | 2025-04-17 | Chengdu Ucello Biotechnology Co., Limited | Engineered immune cells and uses thereof |
| CN117186202B (zh) * | 2023-11-08 | 2024-02-02 | 北京大学第三医院（北京大学第三临床医学院） | 一种新细胞因子csbf及其在干眼治疗中的应用 |
| CN117866110B (zh) * | 2023-12-27 | 2024-06-11 | 广东唯泰生物科技有限公司 | 一种靶向flt-3的第四代嵌合抗原受体及其应用 |
| CN119345372A (zh) * | 2024-10-28 | 2025-01-24 | 北京大学人民医院 | Cd132在治疗aml中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230297T1 (hr) | 2012-07-13 | 2023-05-12 | The Trustees Of The University Of Pennsylvania | UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| CA2939411A1 (en) * | 2014-02-27 | 2015-09-03 | Ucl Business Plc | Ligand |
| KR102763121B1 (ko) * | 2015-02-06 | 2025-02-04 | 내셔널 유니버시티 오브 싱가포르 | 치료적 면역 세포의 효능의 향상 방법 |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| EP4628587A3 (en) * | 2016-04-15 | 2026-02-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| KR102546839B1 (ko) | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
| WO2018064602A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| CN106636090B (zh) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| CA3048648A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| AU2018345751A1 (en) * | 2017-10-02 | 2020-05-07 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| KR20200075851A (ko) | 2017-10-19 | 2020-06-26 | 셀렉티스 | 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합 |
| AU2018370217A1 (en) | 2017-11-17 | 2020-05-28 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for alleviating Cytokine Release Syndrome |
| EP3802578A4 (en) | 2018-06-01 | 2022-03-23 | Washington University | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY |
-
2019
- 2019-05-31 EP EP19810633.8A patent/EP3802578A4/en not_active Withdrawn
- 2019-05-31 JP JP2020567078A patent/JP2021525530A/ja active Pending
- 2019-05-31 WO PCT/US2019/034981 patent/WO2019232425A1/en not_active Ceased
- 2019-05-31 CN CN201980044894.5A patent/CN112533942A/zh active Pending
- 2019-05-31 US US16/428,362 patent/US20200054675A1/en not_active Abandoned
-
2022
- 2022-05-17 US US17/746,645 patent/US12304941B2/en active Active
-
2025
- 2025-03-19 US US19/084,433 patent/US20260022156A1/en active Pending